NephJC is a nephrology journal club that uses Twitter to discuss the research, guidelines, and editorials that are driving nephrology forward.
This week, we will maybe not expect the worse, while discussing the COMPASS post hoc analysis. Are PPIs so bad for the kidneys?
This week, we will discuss the blockbuster trial of 2024, FLOW. GLP1RAs have arrived in the nephrology realm.
This week, we will discuss the second part of the 2024 CKD guidelines from KDIGO. Lots to chew on, so let’s dive in!
This week, we will discuss the 2024 KDIGO Guidelines on CKD, part 1. In this section we will discuss the first two chapters on CKD evaluation and risk stratification. Let’s dive in!
This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week on NephTrials we will discuss the PROTECT-V trial, a platform trial for preventing COVID-19 infections in the vulnerable kidney populations.
This week, we will discuss the SLEEP-HD trial, which examined if trazodone or CBT are better than placebo in helping people sleep.
This week, we will discuss the recently published KDIGO lupus guidelines. Published a couple of years after the big GN guidelines - let us dive in to see what’s new in lupus nephritis
This week, we will be discussing a randomized controlled trial of eculizumab in STEC-HUS. Will eculizumab manage to surpass its well-established reputation as expensivumab and demonstrate some positive results?
2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!
This week we will discuss the article from Lancet on the addition of an ASI to background RASi and empagliflozin. Did this work?
This week, the last 2023’ NephJC resurfaces an old dilemma, in a different SPACE- non-cardiac surgery. Should we STOP ACEi, or do we know better?
This week, we will discuss yet another endothelin antagonist trial, on a background of flozins, in proteinuric CKD. Will flozins help breakthrough the endothelin badness?
This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?
This week on #NephTrials, we will discuss platform trials, anchoring the discussion to the BEAT-Calci trial, which has a number of interesting design features.
This week, nephrologists hope they found the key to no-dialysis-land, where kindness and detailed, multistep interventions make the path to kidney transplant much easier. This was foreseen in our Freely Filtered episode and disputed during #KidneyWK 2023 late-breaking clinical trials session. Still, when it comes to RCTs’ results, will it be Deja Vu or a happy ending?
This week, we will have a salty debate on what nephrologists love the most: hyponatremia and numbers. The main question: are guideline hyponatremia rates a waste of time?
This week on NephJC we are hashing out the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial!
This week, we will discuss some groundbreaking work on elucidating the adaptive and maladaptive cellular transcription and gene activation of the kidney in healthy and diseased states.
Classic scenario: young doctor, old patient with asymptomatic hypertension…
This week we are going against our instinct to normalize blood pressure numbers and listening to our wise elders.
What do you do when you suspect AIN (and eosinophils aren’t helpful) and you can’t get a kidney biopsy? CXCL9 is a newly discovered urinary marker that may help in the diagnosis of AIN. This week we will discuss the process of isolating and utilizing this new diagnostic test.
Help keep NephJC a vital, original, and unbiased source of medical education.
This week, we put our best fluid forward to discuss whether balanced crystalloids reduce the incidence of DGF after deceased donor kidney transplant compared to normal saline.
In this edition of NephTrials, we will discuss the importance of PROS, PROMS, PREMS, anchoring the discussion to the SWIFT trial
This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?
This week, we will discuss a systematic review challenging a common practice: the use of sodium thiosulfate in calciphylaxis.
This week, we will discuss the effects of oral bicarbonate therapy in kidney transplant recipients.
Preserve-Transplant Study from Lancet.
All scheduled chats are tentative. We may change the schedule depending on the whims of the NephJC work group
June 11, 12: Semaglutide and CKD, the FLOW trial (Perkovic et al, NEJM 2024)
June 25, 26: The Effects of Pantoprazole on Kidney Outcomes: Post Hoc Observational Analysis from the COMPASS Trial (Pyne et al, JASN 2024)
July 9, 10 Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort (Wong et al, Lancet 2024)
July 23, 24 Hypertension and Kidney Function After Living Kidney Donation (Garg et al, 2024 JAMA 2024)
Aug 6, 7 Amino acid Infusions in AKI (PROTECTION, Landoni et al, NEJM 2024)
August 20, 21 NephJC Summer Bookclub The Covenant of Water by Abraham Verghese (Amazon)
Twice a month (that’s aspirational, not a promise), the filtrate (Jennie Lin, Joel Topf, Jordy Cohen, Joshua Waitzman, Nayan Arora, Sophia Ambruso, and Swapnil Hiremath) sit down and recap the latest NephJC discussion. We go as deep as it takes. Give it a listen.
Nefecon, coated budesonide, is the first drug labelled for IgA nephropathy and the approval path, 9-month reduction in proteinuria followed by 2 year GFR data set the stage for the GN renaissance we are currently living through.
On May 24th, at the ERA meeting in Stockholm Sweden (this will not be the last GLP1ra talk at Stockholm), Vlado Perkovic presented the previously spoiled results of FLOW. In addition to simultaneous publication in the NEJM, it made the front page in newspapers around the world. As one headline writer said, “Is there anything Ozempic can’t do?”
Preeclampsia is scarry. Wouldn’t be great if we a blood test to predict which patients would develop severe pre-eclampsia? Well maybe, just maybe the sFlt-1 to PlGF ratio could answer this prayer.
See the blog post describing this inititiative.
In the last year, NephJC has injected some statistical muscle into its editorial team (thank you Perry Wilson and Laurie Tomlinson). Then Manasi Bapat volunteered to create some cogent explainers for the various techniques that are routinely described in the methods section most of us skip over as we rush to the results. Here are the recent posts...
This week on NephTrials we will discuss the PROTECT-V trial, a platform trial for preventing COVID-19 infections in the vulnerable kidney populations.
This week on #NephTrials, we will discuss platform trials, anchoring the discussion to the BEAT-Calci trial, which has a number of interesting design features.
In this edition of NephTrials, we will discuss the importance of PROS, PROMS, PREMS, anchoring the discussion to the SWIFT trial
In this edition of NephTrials, we will discuss the bewildering world of master protocols, comprising of platform, umbrella and basket trials - with the example of the RENAL LIFECYCLE trial.
The next #Nephtrials discussion will feature a deep dive into convection/hemodiafiltration, and the ongoing registry based trial, H4RT
After cluster RCTs and pragmatic trials, we will discuss the role of run in periods and what we try to achieve by having them in clinical trials. Read on.
This week we discuss cluster RCTs. How do you conduct, consent, analyse and interpret these? Why do you do cluster RCTs? Let’s discuss using the Dial-Mag trial as an example.
Join us for the first edition of the #NephTrials chat. Let’s take a deep dive into pragmatic trials, and take a specific example - the Phosphate trial, to anchor the discussion.
NephTrials: where NephJC joins forces with ISN ACT and ISN Academy, to bring the social media expertise from the NephJC community and the methods expertise from ISN-ACT.
In this edition of #Nephstats, we look at Number Needed to Treat (NNT), a controversial topic creates ripples and roars on social media amongst stat savvy physicians, epidemiologists and biostatisticians. This seems like such a simple and easy number to make sense of a trial’s importance - what could be controversial or wrong about it?
2023 Perry Wilson How Medicine Works and When It Doesn't
2022 Walter Isaacson The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race
2021 Joshua D Mezrich When Death Becomes Life: Notes from a Transplant Surgeon
2020 Rana Awdish’s In Shock
2019 Andrew Bomback’s Doctor (Object Lessons)
2018 Siddhartha Mukherjee's Laws of Medicine, Field Notes from an Uncertain Science
2017 Vanessa Grubb's Hundreds of Interlaced Fingers.
2016 Eric Topol's The Patient Will See You Now
2015 Atul Gawande's Being Mortal